SUPERNUS PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent of -$614.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent · last filed 2018-05-10
- SUPERNUS PHARMACEUTICALS, INC. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for the quarter ending 2018-03-31 was -$614.00K.
- SUPERNUS PHARMACEUTICALS, INC. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for the quarter ending 2017-03-31 was $0.00.
| Period end | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent 3 month |
|---|---|
| 2018-03-31 | -$614.00K 10-Q · filed 2018-05-10 |
| 2017-03-31 | $0.00 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |